Suneva Medical Launches 30 mL PRP Gel Tubes of Amplifine; Will Provide Patients And Practices With A Larger Volume Of PRP To Address Varying Areas Of Concern More Efficiently

SAN DIEGO, Sept. 13, 2022 /PRNewswire/ -- Suneva Medical, Inc. ("Suneva" or the "Company"), an innovative medical technology company using regenerative products to change the standard of care in patient treatments, today launched the 30 mL iteration of their Amplifine Platelet Rich Plasma (PRP) gel tubes, which will provide patients and practices with a larger volume of PRP to address varying areas of concern more efficiently. The 30 mL PRP tubes received a 510(k) clearance by the U.S. Food and Drug Administration (FDA) earlier this year.

Suneva's Amplifine PRP gel tubes use a proprietary gel, designed to capture a high concentration of platelets in a short processing time, delivering clinical benefits to patients while also making the clinical practice more efficient by offering a wider array of regenerative treatments to their patients in an emerging and vast regenerative medicine market in North America.

PRP is a regenerative treatment that allows providers to access the patient's natural growth factors, via centrifugation of the patient's blood, in order to separate the red and white blood cells and concentrate the platelets.

"We are building upon our PRP platform with the launch of Amplifine's 30mL PRP gel tube, so both patients and providers will be getting the greatest value when performing or receiving their PRP treatment of choice," said Pat Altavilla, Chief Executive Officer of Suneva. "Our commitment to offering the best products in regenerative aesthetic practices and patients is stronger than ever, as we continue to find new ways to optimize our portfolio of minimally invasive and high impact aesthetic treatments."

The availability of the Amplifine 30mL PRP gel tube directly addresses the growing demand from practices and their patients to capture a higher volume of PRP for various clinical applications. As part of Amplfine's PRP platform, the new 30mL gel tubes will offer larger volume PRP while maintaining the key features that practices have come to expect: practice efficiency with a short 10-minute processing time, the ability to capture a high concentration of platelets and a safe and effective product that has been cleared by the FDA.

On January 12, 2022, Suneva Medical and Viveon Health Acquisition Corp. (NYSE:VHAQ) ("Viveon Health" or "VHAQ"), a special purpose acquisition company, announced that they entered into a definitive merger agreement. Upon completion of the transaction, the combined company's securities are expected to be traded as an autonomous entity.